Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2012
  • Online publication date: August 2012

10 - Testosterone and cardiovascular disease

10.12 References

AgledahlI, HansenJB, SvartbergJ (2008) Postprandial triglyceride metabolism in elderly men with subnormal testosterone levels. Asian J Androl 10:542–549
AkishitaM, HashimotoM, OhikeY, OgawaS, IijimaK, EtoM, OuchiY (2010) Low testosterone level as a predictor of cardiovascular events in Japanese men with coronary risk factors. Atherosclerosis 210:232–236
AlexandersenP, HaarboJ, ByrjalsenI, LawaetzH, ChristiansenC (1999) Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Research 84:813–819
AndersenNH, BojesenA, KristensenK, BirkebaekNH, FedderJ, BennettP, ChristiansenJS, GravholtCH (2008) Left ventricular dysfunction in Klinefelter syndrome is associated to insulin resistance, abdominal adiposity and hypogonadism. Clin Endocrinol (Oxf) 69:785e91
AndersonFH, FrancisRM, FaulknerK (1996) Androgen supplementation in eugonadal men with osteoporosis – effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone 18:171–177
AndersonRA, LudlamCA, WuFCW (1995b) Haemostatic effects of supraphysiological levels of testosterone in normal men. Thromb Haemostasis 74:693–697
AndersonTJ, UehataA, GerhardMD, MeredithIT, KnabS, De La GrangeD, LiebermanEH, GanzP, CreagerMA, YeungAC, SelwynAP (1995a) Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26:1235–1241
AnkerSD, CoatsAJ (2002) How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol 86:123–130
AnkerSD, ChuaTP, PonikowskiP, HarringtonD, SwanJW, KoxWJ, Poole-WilsonPA, CoatsAJ (1997) Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 96:526–534
AradY, BadimonJJ, BadimonL, HembreeWC, GinsbergHN (1989) Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in the cholesterol-fed rabbit. Arteriosclerosis 9:159–166
BagatellCJ, HeimanJR, MatsumotoAM, RivierJE, BremnerWJ (1994) Metabolic and behavioral effects of high dose exogenous testosterone in healthy men. J Clin Endocrinol Metab 79:561–567
Barrett-ConnorE (1992) Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Int Med 117:807–811
Barrett-ConnorE, KhawKT (1988) Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78:539–545
BasariaS, CovielloAD, TravisonTG, StorerTW, FarwellWR, JetteAM, EderR, TennstedtS, UlloorJ, ZhangA, ChoongK, LakshmanKM, MazerNA, MiciekR, KrasnoffJ, ElmiA, KnappPE, BrooksB, ApplemanE, AggarwalS, BhasinG, Hede-BrierleyL, BhatiaA, CollinsL, LeBrasseurN, FioreLD, BhasinS (2010) Adverse events associated with testosterone administration. N Engl J Med 363:109–122
BavenholmP, de FaireU, LandouC, EfendicS, NilssonJ, WilmanB, HamstenA (1998) A progression of coronary artery disease in young male post-infarction patients is linked to disturbances of carbohydrate and lipoprotein metabolism and to impaired fibrinolytic function. Eur Heart J 19:402–410
BeboBF, SchusterJC, VandenbarkAA, OffnerH (1999) Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J Immunol 162:35–40
BeerNA, JakubowiczDJ, MattDW, BeerRM, NestlerJE (1996) Dehydroepiandrosterone reduces plasma plasminogen activator inhibitor type 1 and tissue plasminogen activator antigen in men. Am J Med Sci 311:205–210
BollaM, Van TienhovenG, WardeP, DuboisJB, MirimanoffRO, StormeG, BernierJ, KutenA, SternbergC, BillietI, TorrecillaJL, PfefferR, CutajarCL, Van der KwastT, ColletteL (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11:1066–1073
BourghardtJ, WilhelmsonAS, AlexandersonC, De GendtK, VerhoevenG, KrettekA, OhlssonC, TivestenA (2010) Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology 151:5428–5437
BowlesDK, MaddaliKK, GanjamVK, RubinLJ, TharpDL, TurkJR, HeapsCL (2004) Endogenous testosterone increases L-type Ca2+ channel expression in porcine coronary smooth muscle. Am J Physiol 287:H2091–H2098
BruckB, BrehmeU, GugelN, HankeS, FinkingG, LutzC, BendaN, SchmahlFW, HaasisR, HankeH (1997) Gender-specific differences in the effects of testosterone and estrogen on the development of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 17:2192–2199
CaminitiG, Volterrani, M, IellamoF, MarazziG, MassaroR, MiceliM, MammiC, PiepoliM, FiniM, RosanoGMC (2009) Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. A double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 54:919–927
CaronP, BennetA, CamareR, LouvetJP, BoneuB, SieP (1989) Plasminogen activator inhibitor in plasma is related to testosterone in men. Metab Clin Exper 38:1010–1015
ChouTM, SudhirK, HutchisonSJ, KoE, AmidonTM, CollinsP, ChatterjeeK (1996) Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo. Circulation 94:2614–2619
ChuteCG, BaronJA, PlymateSR, KielDP, PaviaAT, LoznerEC, O'KeefeT, MacDonaldGJ (1987) Sex hormones and coronary artery disease. Am J Med 83:853–859
CoatsAJ (2001) Heart failure: what causes the symptoms of heart failure?Heart 86:574–578
CoronaG, MonamiM, BoddiV, Cameron-SmithM, FisherA, de VitaG, MelaniC, BalziD, SforzaA, FortiG, MannucciE, MaggiM (2010) Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. J Sex Med 7:1557–1564
CorralesJJ, AlmeidaM, BurgoR, MoriesMT, MirallesJM, OrfaoA (2006) Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol 189:595–604
CovielloAD, KaplanB, LakshmanKM, ChenT, SinghAB, BhasinS (2008) Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 93:914–919
CrewsJK, KhalilRA (1999a) Antagonistic effects of 17 beta-estradiol, progesterone, and testosterone on Ca2+ entry mechanisms of coronary vasoconstriction. Art Thromb Vasc 19:1034–1040
CrewsJK, KhalilRA (1999b) Gender-specific inhibition of Ca2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin Exp Pharmacol & Physiol 26:707–715
D'AgostinoP, MilanoS, BarberaC, Di BellaG, La RosaM, FerlazzoV, FarruggioR, MiceliDM, MieleM, CastagnettaL, CillariE (1999) Sex hormones modulate inflammatory mediators produced by macrophages. Ann NY Acad Sci 876:426–429
DavoodiG, AmirezadeganA, BorumandMA, DehkoriMR, KazemisaeidA, YaminisharifA (2007) The relationship between level of androgenic hormones and coronary artery disease in men. Cardiovasc J Africa 18:362–366
DebingE, PeetersE, DuquetW, PoppeK, VelkeniersB, Van Den BrandeP (2008) Men with atherosclerotic stenosis of the carotid artery have lower testosterone levels compared with controls. Int Angiol 27:135–141
DeenadayaluVP, WhiteRE, StalloneJN, GaoX, GarciaAJ (2001) Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol – Heart C 281:H1720–H1727
DemirbagR, YilmazR, UlucayA, UnluD (2005) The inverse relationship between thoracic aortic intima media thickness and testosterone level. Endocr Res 31:335–344
De PergolaG, De MitrioV, SciaraffiaM, PannacciulliN, MinennaA, GiorginoF, PetronelliM, LaudadioE, GiorginoR (1997) Lower androgenicity is associated with higher plasma levels of pro-thrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. Metabolism 46:1287–1293
DingAQ, StalloneJN (2001) Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K+ channel activation. J Appl Physiol 91:2742–2750
DobrzyckiS, SerwatkaW, NadlewskiS, KoreckiJ, JackowskiR, ParukJ, LadnyJR, HirnleT (2003) An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. Med Invest 50:162–169
EichDM, NestlerJE, JohnsonDE, DworkinGH, KoD, WechslerAS, HessML (1993) Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation 87:261–269
EnglishKM, MandourO, SteedsRP, DiverMJ, JonesTH, ChannerKS (2000a) Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 21:890–894
EnglishKM, JonesRD, JonesTH, MoriceAH, ChannerKS (2000b) Aging reduces the responsiveness of coronary arteries from male Wistar rats to the vasodilatory action of testosterone. Clin Sci 99:77–82
EnglishKM, SteedsRP, JonesTH, DiverMJ, ChannerKS (2000c) Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 102:1906–1911
EnglishKM, JonesRD, JonesTH, MoriceAH, ChannerKS (2001) Gender differences in the vasomotor effects of different steroid hormones in rat pulmonary and coronary arteries. Horm Metab Res 33:645–652
EnglishKM, JonesRD, JonesTH, MoriceAH, ChannerKS (2002) Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest 25:455–458
GentileMA, NantermetPV (2010) Androgen mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF-1, MGF and induction of beta-catenin. J Mol Endocrinol 44:55e73
GliczynskiS, OssowskiM, Slowinska-SrzednickaJ, BrzezinskaA, ZgliczynskiW (1996) Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men. Atherosclerosis 121:35–43
GlueckCJ, GlueckHI, StroopD, SpeirsJ, HamerT, TracyT (1993) Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J Lab Clin Med 122:412–420
GordonGB, BushDE, WeismanHF (1988) Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in hypercholesterolaemic New Zealand White rabbits with aortic intimal injury. J Clin Invest 82:712–720
GradyD, HerringtonD, BittnerV, BlumenthalR, DavidsonM, HlatkyM, HsiaJ, HulleyS, HerdA, KhanS, NewbyLK, WatersD, VittinghoffE, WengerN; HERS Research Group (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy (HERS II). JAMA 288:49–57
GuderG, FratzS, BauersachSJ, AllolioB, ErtlG, AngermannCE, StorkS (2010) Low serum androgens and mortality in heart failure. Heart 96:504–509
HaffnerSM, MykkanenL, ValdezRA, KatzMS (1993) Relationship of sex hormones to lipids and lipoproteins in non-diabetic men. J Clin Endocrinol Metab 77:1610–1615
HakAE, WittemanJC, de JongFH, GeerlingsMI, HofmanA, PolsHA (2002) Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 87:3632–3639
HallJ, JonesRD, JonesTH, ChannerKS, PeersC (2006) Selective inhibition of L-type Ca2+ channels in A7r5 cells by physiological levels of testosterone. Endocrinology 147:2675–2680
HammL (1942) Testosterone propionate in the treatment of angina pectoris. J Clin Endocrinol 2:325–328
HankeH, LenzC, SpindlerKD, WeidemannW (2001) Effect of testosterone on plaque development and androgen receptor expression in the arterial vessel wall. Circulation 103:1382–1385
HaringB, VolzkeH, StevelingA, KrebsA, FelixSB, SchoflC, DorrM, NauckM, WallaschofskiH (2010) Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20–79. Eur Heart J 31:1491–1501
HatakeyamaH, NishizawaM, NakagawaA, NakanoS, KigoshiT, UchidaK (2002) Testosterone inhibits tumor necrosis factor-alpha-induced vascular cell adhesion molecule-1 expression in human aortic endothelial cells. FEBS Letters 530:129–132
HaunerH, StanglK, BurgerK, BuschU, BlömerH, PfeifferEF (1991) Sex hormone concentrations in men with angiographically assessed coronary artery disease – relationship to obesity and body fat distribution. Klin Wsch 69:664–668
HermanSM, RobinsonJC, McCredieRJ, AdamsMR, BoyerMJ, CelermajerDS (1997) Androgen deprivation is associated with enhanced endothelium-dependent dilatation in adult men. Arterioscler Thromb Vasc Biol 17:2004–2009
HondaH, UnemotoT, KogoH (1999) Different mechanisms for testosterone-induced relaxation of aorta between normotensive and spontaneously hypertensive rats. Hypertension 34:1232–1236
HowellSJ, RadfordJA, AdamsJE, SmetsEM, WarburtonR, ShaletSM (2001) Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol 55:315–324
HulleyS, GradyD, BushT, FurbergC, HerringtonD, RiggsB, VittinghofE (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280:605–613
IellamoF, VolterraniM, CaminitiG, KaramR, MassaroR, FiniM, CollinsP, RosanoGMC (2010) Testosterone therapy in women with chronic heart failure. A pilot double-blind, randomized, placebo-controlled study. J Am Coll Cardiol 256:1310–1316
IsidoriAM, GiannettaE, GrecoEA, GianfrilliD, BonifacioV, IsidoriA, LenziA, FabbriA (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 63:280–293
JaffeMD (1977) Effect of testosterone cypionate on postexercise ST segment depression. Br Heart J 39:1217–1222
JankowskaEA, BielB, MajdaJ, SzklarskaA, LopuszanskaM, MedrasM, AnkerSD, BanasiakW, Poole-WilsonPA, PonikowskiP (2006) Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 114:1829–1837
JonesRD, EnglishKM, PughPJ, MoriceAH, JonesTH, ChannerKS (2002) Pulmonary vasodilatory action of testosterone: evidence of a calcium antagonistic action. J Cardiovasc Pharmacol 39:814–823
JonesRD, PughPJ, HallJ, ChannerKS, JonesTH (2003a) Altered circulating hormone levels, endothelial function and vascular reactivity in the testicular feminised mouse. Eur J Endocrinol 148:111–120
JonesRD, PughPJ, JonesTH, ChannerKS (2003b) The vasodilatory action of testosterone: a potassium channel opening or a calcium antagonistic action?Br J Pharm 138:733–744
JonesRD, RubanLN, MortonIE, RobertsSA, EnglishKM, ChannerKS, JonesTH (2003c) Testosterone inhibits the prostaglandin F-2-alpha mediated increase in intracellular calcium in A7r5 aortic smooth muscle cells: evidence of an antagonistic action upon store-operated calcium channels. J Endocrinol 178:381–393
JonesRD, EnglishKM, JonesTH, ChannerKS (2004a) Testosterone-induced coronary vasodilatation occurs via a non-genomic mechanism: evidence of a direct calcium antagonistic action. Clin Sci 107:149–158
JonesRD, JonesTH, ChannerKS (2004b) The influence of testosterone upon vascular reactivity. Eur J Endocrinol 151:29–37
JonesTH, SaadF (2009) The effects of testosterone on risk factors for, and mediators of, the atherosclerotic process. Atherosclerosis 207:308–327
JonesTH, ArverS, BehreH, BuvatJ, MeulemanE, IrribarrenIM, MoralesA, VolterraniM, YellowleesA, HowellJD, ChannerKS (2011) Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 34:828–837
KabakciG, YildirirA, CanI, UnsalI, ErbasB (1999) Relationship between endogenous sex hormone levels, lipoproteins and coronary atherosclerosis in men undergoing coronary angiography. Cardiology 92:221–225
KandaN, TsuchidaT, TamakiK (1996) Testosterone inhibits immunoglobulin production by human peripheral blood mononuclear cells. Clin Exper Immunol 106:410–415
KandaN, TsuchidaT, TamakiK (1997) Testosterone suppresses anti-DNA antibody production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum 40:1703–1711
KangSM, JangY, KimJY, ChungN, ChoSY, ChaeJS, LeeJH (2002) Effect of oral administration of testosterone on brachial arterial vasoreactivity in men with coronary artery disease. Am J Cardiol 89:862–864
KapoorD, MalkinCJ, ChannerKS, JonesTH (2005) Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 63:239–250
KapoorD, GoodwinE, ChannerKS, JonesTH (2006) Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 154:899–906
KarakitsosD, PatrianakosAP, De GrootE, BoletisJ, KarabinisA, KyriazisJ, SamonisG, ParthenakisFI, VardasPE, DaphnisE (2006) Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am J Nephrol 26:536–543
KeatingNL, O'MalleyAJ, SmithMR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Onc 24:4448–4456
KemppainenJ, TsuchidaH, StolenK, KarlssonH, BjornholmM, HeinonenOJ, NuutilaP, KrookA, KnuutiJ, ZierathJR (2003) Insulin signalling and resistance in patients with chronic heart failure. J Physiol 550 (Pt 1):305–315
KhawKT, DowsettM, FolkerdE, BinghamS, WarehamN, LubenR, WelchA, DayN (2007) Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116:2694–2701
KhoslaS, AtkinsonEJ, DunstanCR, O'FallonWM (2002) Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550–1554
KontoleonPE, Anastasiou-NanaMI, PapapetrouPD, AlexopoulosG, KtenasV, RaptiAC, TsagalouEP, NanasJN (2003) Hormonal profile in patients with congestive heart failure. Int J Cardiol 87:179–183
KotechaD, NgoK, WaltersJA, ManzanoL, PalazzuoliA, FlatherMD (2011) Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J 161:822–831.e2
LarsenBA, NordestgaardBG, StenderS, KjeldsenK (1993) Effect of testosterone on atherogenesis in cholesterol-fed rabbits with similar plasma cholesterol levels. Atherosclerosis 99:79–86
LaughlinGA, Barrett-ConnorE, BergstromJ (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68–75
LesserMA (1946) Testosterone propionate therapy in one hundred cases of angina pectoris. J Clin Endocrinol 6:549–557
LevineGN, D'AmicoAV, BergerP, ClarkPE, EckelRH, KeatingNL, MilaniRV, SagalowskyAI, SmithMR, ZakaiN; American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, the American Cancer Society, and the American Urological Association (2010) Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 121:833–840
LiS, LiX, LiY (2008) Regulation of atherosclerotic plaque growth and stability by testosterone and its receptor via influence of inflammatory reaction. Vascul Pharmacol 49:14–18
LiZ, DanisV, BrooksP (1993) Effect of gonadal steroids on the production of IL-1 and IL-6 by blood mononuclear cells in vitro. Clin Exp Rheumatol 11:157–162
LivaSM, VoskuhlRR (2001) Testosterone acts directly on CD4(+) T lymphocytes to increase IL-10 production. J Immunol 167:2060–2067
LusisA (2000) Atherosclerosis. Nature 407:233–241
LyLP, JimenezM, ZhuangTN, CelermajerDS, ConwayAJ, HandelsmanDJ (2001) A double-blind, placebo-controled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiency. J Clin Endocrinol Metab 86:4078–4088
MaggioM, LauretaniF, CedaGP, BandinelliS, LingSM, MetterEJ, ArtoniA, CarassaleL, CazzatoA, CeresiniG, GuralnikJM, BasariaS, ValentiG, FerrucciL (2007) Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti area (InCHIANTI) study. Arch Intern Med 167:2249–2254
MakinenJ, JarvisaloMJ, PollanenP, PerheentupaA, IrjalaK, KoskenvuoM, MakinenJ, HuhtaniemiI, RaitakariOT (2005) Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 45:1603–1608
MäkinenJI, PerheentupaA, IrjalaK, PöllänenP, MäkinenJ, HuhtaniemiI, RaitakariOT (2008) Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis 197:688–693
MalkinCJ, PughPJ, MorrisPD, KerryKE, JonesRD, JonesTH, ChannerKS (2004a) Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart 90:871–876
MalkinCJ, PughPJ, JonesRD, KapoorD, ChannerKS, JonesTH (2004b) The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 89:3313–3318
MalkinCJ, JonesRD, JonesTH, ChannerKS (2006a) Effect of testosterone on ex vivo vascular reactivity in man. Clin Sci (Lond) 111:265–274
MalkinCJ, PughPJ, WestJN, van BeekEJ, JonesTH, ChannerKS (2006b) Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J 27:57–64
MalkinCJ, JonesTH, ChannerKS (2007) The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail 9:44–50
MalkinCJ, PughPJ, MorrisPD, AsifS, JonesTH, ChannerKS (2010) Low serum testosterone and increased mortality in men with coronary heart disease. Heart 96:1821–1825
MårinP, HolmängS, GustafssonC, JönssonL, KvistH, ElanderA, EldhJ, SjöströmL, HolmG, BjörntorpP (1993) Androgen treatment of abdominally obese men. Obes Res 1:245–251
MathurA, MalkinC, SaeedB, MuthasamyS, JonesTH, ChannerKS (2009) The long term effect of testosterone replacement therapy on angina threshold and atheroma in patients with chronic stable angina. Eur J Endocrinol 161:443–449
McCrohonJA, JessupW, HandelsmanDJ, CelermajerDS (1999) Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1. Circulation 99:2317–2322
McRobbL, HandelsmanDJ, HeatherAK (2009) Androgen-induced progression of arterial calcification in apolipoprotein E-null mice is uncoupled from plaque growth and lipid levels. Endocrinology 150:841–848
MinnemannT, SchubertM, HüblerD, Gouni-BertholdI, FreudeS, SchumannC, OettelM, ErnstM, MellingerU, SommerF, KroneW, JockenhövelF (2007) A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoateAging Male 10:155–158
MukherjeeTK, DinhH, ChaudhuriG, NathanL (2002) Testosterone attenuates expression of vascular cell adhesion molecule-1 by conversion to estradiol by aromatase in endothelial cells: implications in atherosclerosis. Natl Acad Sci USA 99:4055–4060
MullerM, van den BeldAW, BotsML, GrobbeeDE, LambertsSW, van der SchouwYT (2004) Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109:2074–2079
MurphyJG, KhalilRA (1999) Decreased [Ca(2+)](i) during inhibition of coronary smooth muscle contraction by 17beta-estradiol, progesterone, and testosterone. J Pharmacol Exp Ther 291:44–52
NathanL, ShiWB, DinhH, MukherjeeTK, WangXP, LusisAJ, ChaudhuriG (2001) Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Natl Acad Sci USA 98:3589–3593
NettleshipJE, JonesTH, ChannerKS, JonesRD (2007a) Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: an effect that is independent of the classic androgen receptor. Circulation 116:2427–2434
NettleshipJE, PughPJ, ChannerKS, JonesT, JonesRD (2007b) Inverse relationship between serum levels of interleukin-1beta and testosterone in men with stable coronary artery disease. Horm Metab Res 39:366–371
OngPJ, PatriziG, ChongWC, WebbCM, HaywardCS, CollinsP (2000) Testosterone enhances flow-mediated brachial artery reactivity in men with coronary artery disease. Am J Cardiol 85:269–272
PerusquiaM, VillalonCM (1999) Possible role of Ca2+ channels in the vasodilating effect of 5 beta-dihydrotestosterone in rat aorta. Eur J Pharmacol 371:169–178
PerusquiaM, HernandezR, MoralesMA, CamposMG, VillalonCM (1996) Role of endothelium in the vasodilating effect of progestins and androgens on the rat thoracic aorta. Gen Pharmacol 27:181–185
PhillipsGB, PinkernellBH, JingTY (1994) The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 14:701–706
PhillipsGB, JingTY, LaraghJH, SealeyJE (1995) Serum sex hormone levels and renin-sodium profile in men with hypertension. Am J Hypertens 8:626–629
PhillipsGB, PinkernellBH, JingTY (2004) Are major risk factors for myocardial infarction the major predictors of degree of coronary artery disease in men?Metabolism 53:324–359
PourHRN, GrobbeeDE, BotsML, VerhaarHJJ, MullerM, van der SchouwYT (2007) Circulating sex hormone levels and aortic stiffness in men. JAGS 55:621–637
PughPJ, JonesRD, JonesTH, ChannerKS (2002a) Intrinsic responses of rat coronary arteries in vitro: influence of testosterone, calcium and effective transmural pressure. Endocrine 19:155–162
PughPJ, ChannerKS, ParryH, DownesT, JonesTH (2002b) Bio-available testosterone levels fall acutely following myocardial infarction in men: association with fibrinolytic factors. Endocrine Res 28:161–173
PughPJ, JonesTH, ChannerKS (2003) Acute haemodynamic effects of testosterone in men with chronic heart failure. Eur Heart J 24:909–915
PughPJ, JonesRD, WestJN, JonesTH, ChannerKS (2004) Testosterone treatment for men with chronic heart failure. Heart 90:446–447
PughPJ, JonesRD, MalkinCJ, HallJ, NettleshipJE, KerryKE (2005) Physiologic testosterone therapy has no effect on serum levels of tumour necrosis factor-alpha in men with chronic heart failure. Endocr Res 31:271–283
QiuY, YanaseT, HuH, TanakaT, NishiY, LiuM, SueishiK, SawamuraT, NawataH (2010) Dihydrotestosterone suppresses foam cell formation and attenuates atherosclerosis development. Endocrinology 151:3307–3316
RosanoGM, SheibanI, MassaroR, PagnottaP, MarazziG, VitaleC, MercuroG, VolterraniM, AversaA, FiniM (2007) Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 19:176–182
RosanoGMC, LeonardoF, PagnottaP, PellicciaF, PaninaG, CerquetaniE, della MonicaPL, BonfigliB, VolpeM, ChierchiaSL (1999) Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation 99:1666–1670
RossR (1999) Atherosclerosis: an inflammatory disease. N Engl J Med 340:115–126
RossouwJE, AndersonGL, PrenticeRL, LaCroixAZ, KooperbergC, StefanickML, JacksonRD, BeresfordSA, HowardBV, JohnsonKC, KotchenJM, OckeneJ; Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. JAMA 288:321–333
RowellKO, HallJ, PughPJ, JonesTH, ChannerKS, JonesRD (2009) Mechanisms of agonist-induced constriction in isolated human pulmonary arteries. Vasc Pharmacol 51:8–12
RuigeJB, MahmoudAM, De BacquerD, KaufmanJM (2011) Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart 97:870–875
SaigalCS, GoreJL, KrupskiTL, HanleyJ, SchonlauM, LitwinMS (2007) Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110:1493–1500
SatarianoWA, RaglandKE, Van Den EedenSK (1998) Cause of death in men diagnosed with prostate carcinoma. Cancer 83:1180–1188
ScheuerJ, MalhotraA, SchaibleTF, CapassoJ (1987) Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res 61:12–19
ScraggJL, JonesRD, ChannerKS, JonesTH, PeersC (2004) Testosterone is a potent inhibitor of L-type Ca2+ channels. Biochem Bioph Res Comm 318:503–506
ScraggJL, DallasML, PeersC (2007) Molecular requirements for L-type Ca2+ channel blockade by testosterone. Cell Calcium 42:11–15
ShahaniS, Braga-BasariaM, BasariaS (2008) Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93:2042–2049
ShoresMM, MoceriVM, GruenewaldDA, BrodkinKI, MatsumotoAM, KivlahanDR (2004) Low testosterone is associated with decreased function and increased mortality risk: a preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc 52:2077–2081
ShoresMM, MatsumotoAM, SloanKL, KivlahanDR (2006) Low serum testosterone and mortality in male veterans. Arch Intern Med 166:1660–1665
SiglerLHTJ (1943) Treatment of angina pectoris by testosterone propionate. NY J Med 43:1424–1428
SimonD, PreziosiP, Barrett-ConnorE, RogerM, Saint-PaulM, NahoulK, PapozL (1992) The influence of aging on plasma sex hormones in men: the Telecom Study. Am J Epidemiol 135:783–791
SimonD, CharlesMA, NahoulK, OrssaudG, KremskiJ, HullyV, JoubertE, PapozL, EschwegeE (1997) Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. J Clin Endocrinol Metab 82:682–685
SmithA, EnglishK, MalkinC, JonesR, JonesT, ChannerK (2005) Testosterone does not adversely affect fibrinogen or tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels in 46 men with chronic stable angina. Eur J Endocrinol 152:285–291
SmithAM, BennettRT, JonesTH, CowenME, ChannerKS, JonesRD (2008) Characterisation of the vasodilatory action of testosterone in the human pulmonary circulation. Vasc Health Risk Management 4:1459–1466
SmithJC, BennettS, EvansLM, KynastonHG, ParmarM, MasonMD, CockcroftJR, ScanlonMF, DaviesJS (2001) The effects of induced hypogonadism on arterial stiffness, body composition and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261–4267
SpinediE, SuescunMO, HadidR, DanevaT, GaillardRC (1992) Effects of gonadectomy and sex hormone therapy on the endotoxin-stimulated hypothalamo-pituitary-adrenal axis: evidence for a neuroendocrine-immunological sexual dimorphism. Endocrinology 131:2430–2436
SvartbergJ, von MuhlenD, MathiesenE, JoakimsenO, BonanKH, Stensland-BuggeE (2006) Low testosterone levels are associated with carotid atherosclerosis in men. J Intern Med 259:576–582
SvartbergJ, BraekkanSK, LaughlinGA, HansenJB (2009) Endogenous sex hormone levels in men are not associated with risk of venous thromboembolism: the Tromso study. Eur J Endocrinol 160:833–838
SwedbergK, ClelandJ, DargieH, DrexlerH, FollathF, KomajdaM, TavazziL, SmisethOA, GavazziA, HaverichA, HoesA, JaarsmaT, KorewickiJ, LévyS, LindeC, Lopez-SendonJL, NieminenMS, PiérardL, RemmeWJ; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 26:1115–1140
TaylorLG, CanfieldSE, DuXL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115:2388–2399
TedguiA, MallatZ (2001) Anti-inflammatory mechanisms in the vascular wall. Circ Res 88:877–887
Tedeschi-ReinerE, IvekovicR, Novak-LausK, ReinerZ (2009) Endogenous steroid sex hormones and atherosclerosis of retinal arteries in men. Med Sci Monit 15:211–216
TenoverJS (1992) Effects of testosterone in the aging male. J Clin Endocrinol Metab 75:1092–1098
Tep-areenanP, KendallDA, RandallMD (2002) Testosterone-induced vasorelaxation in the rat mesenteric arterial bed is mediated predominantly via potassium channels. Br J Pharmacol 135:735–740
TharpDL, MasseauI, IveyJ, GanjamVK, BowlesDK (2009) Endogenous testosterone attenuates neointima formation after moderate coronary balloon injury in male swine. Cardiovasc Res 82:152–160
ThogersonAM, JanssonJH, BomanK, NilssonTK, WeinehallL, HuhtasaariF, HallmansG (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98:2241–2247
ThompsonPD, CullinaneEM, SadySP, ChenevertC, SaritelliAL, SadyMA, HerbertPN (1989) Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 261:1165–1168
ThompsonPD, AhlbergAW, MoynaNM, DuncanB, Ferraro-BorgidaM, WhiteCM, McGillCC, HellerGV (2002) Effect of intravenous testosterone on myocardial ischaemia in men with coronary artery disease. Am Heart J 143:249–256
TivestenA, MellströmD, JutbergerH, FagerbergB, LernfeltB, OrwollE, KarlssonMK, LjunggrenO, OhlssonC (2007) Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden. J Am Coll Cardiol 50:1070–1076
TripathyD, ShahP, LakshmyR, ReddyKS (1998) Effect of testosterone replacement on whole body glucose utilisation and other cardiovascular risk factors in males with idiopathic hypogonadotrophic hypogonadism. Horm Metab Res 30:642–645
TsaiHK, D'AmicoAV, SadetskyN, ChenM-H, CarrollPR (2007) Androgen deprivation therapy for localised prostate cancer and the risk of cardiovascular mortality. J Nat Cancer Inst 99:1516–1524
UrhausenA, AlbersT, KindermannW (2004) Are the cardiac effects of anabolic steroid abuse in strength athletes reversible?Heart 90:496–501
UyanikBS, AriZ, GumusB, YigitogluMR, ArslanT (1997) Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. Jap Heart J 38:73–82
VikanT, JohnsenSH, SchirmerH, NjolstadI, SvartbergJ (2009) Endogenous testosterone and the prospective association with carotid atherosclerosis in men: the Tromso study. Eur J Epidemiol 24:289–295
WalkerTC (1942) The use of testosterone propionate and estrogenic substance in the treatment of essential hypertension, angina and peripheral vascular disease. J Clin Endoc 2:560–568
WangC, SwerdloffRS, IranmaneshA, DobsA, SnyderPJ, CunninghamG, MatsumotoAM, WeberT, BermanN; Testosterone Gel Study Group (2000) Transdermal testosterone gel improves sexual function, mood, muscle strength and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 85:2839–2853
WangC, NieschlagE, SwerdloffE, BehreHM, HellstromWJ, GoorenLJ, KaufmanJM, LegrosJ-J, LunenfeldB, MoralesA, MorelyJE, SchulmanC, ThompsonIM, WeldnerW, WuFCW (2008) Investigation, treatment and monitoring of late-onset hypogonadism in males. Consensus statement. Eur J Endocrinol 159:507–514
WangC, IlaniN, ArverS, McLachlanRI, SoulisT, WatkinsonA (2011) Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin Endocrinol (Oxf) 75:836–843. DOI 10.1111/j.1365–2265.2011.04152.x
WebbCM, McNeillJG, HaywardCS, de ZeiglerD, CollinsP (1999a) Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100:1690–1696
WebbCM, AdamsonDL, de ZeiglerD, CollinsP (1999b) Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol 83:437–439
WehrE, PilzS, BoehmBO, MarzW, GrammerT, Obermayer-PietschB (2011) Low free testosterone is associated with heart failure mortality in older men referred for coronary angiography. Eur J Heart Fail 13:482–488
WhitselEA, BoykoEJ, MatsumotoAM, AnawaltBD (2001) Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 111:261–269
WHO (1997) Acute myocardial infarction and combined oral contraceptives: results of an international multi-centre case-control study: WHO collaborative study of cardiovascular disease and steroid hormone contraception. Lancet 349:1202–1209
WuFC, von EckardsteinA (2003) Androgens and coronary artery disease. Endocr Rev 24:183–217
WuSZ, WengXZ (1993) Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients. Chin Med J 106:415–418
YangXC, JingTY, ResnickLM, PhillipsGB (1993) Relation of haemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 13:467–471
YesilovaZ, OzataM, KocarIH, TuranM, PekelA, SengulA, OzdemirIC (2000) The effects of gonadotropin treatment on the immunological features of male patients with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 85:66–70
YueP, ChatterjeeK, BealeC, Poole-WilsonPA, CollinsP (1995) Testosterone relaxes rabbit coronary arteries and aorta. Circulation 91:1154–1160
ZhangX, WangLY, JiangTY, ZhangHP, DouY, ZhaoJH, ZhaoH, QiaoZD, QiaoJT (2002) Effects of testosterone and 17-beta-estradiol on TNF-alpha-induced E-selectin and VCAM-1 expression in endothelial cells. Analysis of the underlying receptor pathways. Life Sci 71:15–29
ZitzmannM, NieschlagE (2007) Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 92:3844–3853
ZitzmannM, BruneM, NieschlagE (2002) Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab 87:5030–5037